ZIRCON
NCT03849118
JCP092
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
Status:
Recruiting
III
Phase
1st
Line of Therapy
Early Cancer
Disease Stage
Biomarker(s)
N/A
Investigational
Product
89Zr-girentuximab
PET/CT imaging
Treatment Arms
o Experimental: 89Zr-girentuximab